Sutro Biopharma (STRO) Payables (2017 - 2025)

Sutro Biopharma has disclosed Payables across 9 years of filings, most recently posting $7.6 million for Q4 2025.

• Payables for Q4 2025 came in at $7.6 million, down 27.78% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.6 million (down 27.78% YoY), and the FY2025 annual result was $7.6 million, down 27.78% from the prior year.
• Payables came in at $7.6 million for Q4 2025 at Sutro Biopharma, up from $7.0 million in the prior quarter.
• In the past five years, Payables ranged from a high of $12.6 million in Q2 2022 to a low of $3.9 million in Q2 2023.
• The 5-year median for Payables is $7.3 million (2024), against an average of $7.6 million.
• Across the five-year window, Payables jumped 129.0% in 2021 and tumbled 69.32% in 2023, its largest moves.
• Sutro Biopharma's Payables stood at $6.0 million in 2021, then retreated by 20.17% to $4.8 million in 2022, then jumped by 96.79% to $9.4 million in 2023, then increased by 10.96% to $10.5 million in 2024, then slipped by 27.78% to $7.6 million in 2025.
• The last three Payables figures came in at $7.6 million (Q4 2025), $7.0 million (Q3 2025), and $4.3 million (Q2 2025), per Business Quant data.